Beam Therapeutics Inc expected to post a loss of $1.36 a share - Earnings Preview

Beam Therapeutics

03/11/2023 13:28

* Beam Therapeutics Inc  BEAM.OQ   BEAM.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 8.3% increase in revenue to $17.115 million from $15.8
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Beam Therapeutics
Inc is
for a loss of $1.36 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $48​, above​ its last closing price of $21.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.46       -1.42      -1.08     Beat    24.2
 Mar. 31 2023  -1.34       -1.34      -1.33     Beat    0.9
 Dec. 31 2022  -1.40       -1.33      -0.54     Beat    59.3​
 Sep. 30 2022  -1.31       -1.31      -1.56     Missed  -18.8
 ​​Jun.        -1.10       -1.08      -1.02     Beat    5.4
 30 2022                                                
 Mar. 31 2022  -1.42       -1.32      -1.01     Beat    23.5​
 Dec. 31 2021  -1.03       -1.03      -0.95     Beat    7.6
 Sep. 30 2021  -0.81       -0.74      -0.42     Beat    43
 This summary was machine generated November 3 at 13:28 GMT.  All
figures in US dollars  unless otherwise stated